RANI - Latest News

Rani Therapeutics Holdings, Inc. (RANI), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $52.0M. Beta to the broader market is 0.69.

The article list below shows the most recent RANI headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent RANI Headlines

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

marketbeat.com - Aug 16, 2026

Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology par

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

globenewswire.com - Aug 13, 2026

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

globenewswire.com - Aug 10, 2026

SAN JOSE, Calif. , Aug.

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com - Jul 20, 2026

SAN JOSE, Calif. , July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

globenewswire.com - Jul 15, 2026

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Ca

How News Affects RANI Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RANI's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked RANI news questions

What is the latest RANI news headline?

The most recent RANI headline (Aug 16, 2026) is "Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the RANI news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What RANI news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual RANI options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.